Jyong Biotech

MENS

Market cap $4.49B

New Taipei City, Taiwan, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd.

New Taipei City, Taiwan, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced that its chairwoman and chief executive officer, Fu Feng Kuo, has been invited to speak at The 2025 Global Business Forum (the “Forum”) on September 19, 2025, at the Taipei International Convention Center.

New Taipei City, Taiwan, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd.

While last month ended up being a decent one for the Nasdaq Composite, it was downright fantastic for a handful of Nasdaq-listed names. Here's a rundown of the Nasdaq Composite's five-best performing stocks that blew the index's 1.6% August gain out of the water.

New Taipei City, Taiwan, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, announced its participation in the 22nd Urological Association of Asia Congress which was held in conjunction with the 47th Annual Meeting of the Taiwan Urological Association on August 14–17, 2025, and exhibited topline results from the multiple clinical studies of its proprietary drug candidates BOTRESO ® for benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), and MCS‑8 (PCP) for the potential prevention of prostate cancer.

Jyong Biotech develops botanical drugs for urinary disorders. Their lead asset is clearly MCS‑2, which is currently restarting Phase 3 trials after a previous FDA setback. Their pipeline targets large unmet BPH, prostate cancer prevention, and IC markets. However, their botanical approach could be a potential “first‑in‑class” as a safer alternative. MENS recent IPO raised roughly $20 million and gave them a healthy cash runway. Though note that additional trials could accelerate cash burn.

New Taipei City, Taiwan, July 22, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, announced completion of its Nasdaq IPO ceremony, and that it participated at the world's largest biotechnology exhibition BIO 2025 International Convention, where it engaged with other global pharmaceutical companies.

A handful of IPOs and blank checks priced in the short holiday week, led by two sizable issuers. Two smaller IPOs also priced this past week. One IPO is currently scheduled to list in the week ahead, although some small names may also join the calendar throughout the week.

New Taipei City, Taiwan, June 18, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced the closing of its initial public offering (the “Offering”) of 2,666,667 ordinary shares (the “Ordinary Shares”) at a public offering price of $7.5 per share for aggregate gross proceeds of approximately $20 million, before deducting underwriting discounts and other offering expenses. The Ordinary Shares commenced trading on Nasdaq Global Market on June 17, 2025, under the ticker symbol “MENS”. The Offering closed on June 18, 2025.